Exondys 51
Customize your policy alerts
Sign up for Cigna Policy IP0135 alerts
Get alerted when Policy IP0135 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage for Exondys 51 (eteplirsen intravenous infusion) for patients with Duchenne muscular dystrophy. Coverage applies when the genetic, functional, age, specialist-prescribing, dosing, and other policy criteria are met.
Initial therapy criteria added a requirement that Duchenne muscular dystrophy be confirmed by a pathogenic or likely pathogenic DMD gene variant amenable to exon 51 skipping.
Initial therapy criteria added a requirement that the patient was younger than 14 years at the start of therapy.
Initial therapy criteria added an ambulation requirement for the patient to be able to walk.
The initial therapy ambulation criterion changed from independently walking at least 180 meters over 6 minutes to being able to walk with submission of baseline 6-minute walk test results.
Initial therapy criteria added that the patient must not have received Elevidys.
Examples of exon-skipping therapies were moved to a note under Conditions Not Covered.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.